Skip to content
Delay leaderboard · updated 18 Nov 2026

Which drug companies run their trials late?

Every active industry trial registered over a year ago, with its planned readout date today compared with the one it first registered. 5,378 trials qualify.

46%pushed their readout back 6+ months
+24 momedian delay among those
45%still on their original date (±1 month)

Listed companies

Companies with at least 30 qualifying trials, ranked by how often they run 6+ months late. Click a company to see its trials on the map.

#CompanyTrialsLate 6+ moOn timeMedian delay
1Pfizer $PFE 9355% 32%+22 mo
2Gilead Sciences $GILD 5254% 42%+31 mo
3Amgen $AMGN 5254% 31%+29 mo
4Hoffmann-La Roche $RO.SW 12648% 40%+25 mo
5AstraZeneca $AZN 25347% 40%+20 mo
6Regeneron Pharmaceuticals $REGN 5847% 36%+23 mo
7AbbVie $ABBV 10546% 47%+33 mo
8Daiichi Sankyo $4568.T 3342% 52%+24 mo
9Novartis Pharmaceuticals $NVS 14242% 41%+30 mo
10Akeso $9926.HK 4040% 57%+29 mo
11Janssen Research & Development, LLC $JNJ 9840% 52%+25 mo
12Eli Lilly and Company $LLY 10438% 50%+17 mo
13Bristol-Myers Squibb $BMY 9238% 53%+23 mo
14Takeda $TAK 5038% 56%+33 mo
15Sanofi $SNY 8738% 52%+20 mo
16GlaxoSmithKline $GSK 8636% 50%+13 mo
17Merck Sharp & Dohme LLC $MRK 14431% 61%+18 mo
18Jiangsu HengRui Medicine Co., Ltd. $600276.SS 4630% 61%+24 mo
19Incyte Corporation $INCY 3330% 64%+20 mo
20Chia Tai Tianqing Pharmaceutical Group Co., Ltd. $1177.HK 4321% 74%+15 mo

By disease area

AreaTrialsLate 6+ moMedian delay
Rare37356% +22 mo
Eye12950% +29 mo
Oncology2,55149% +26 mo
GI·Renal·Heme30346% +27 mo
Neuro45145% +25 mo
Respiratory14043% +15 mo
Infectious30741% +24 mo
Other22841% +22 mo
Immuno38140% +20 mo
Cardio-Met51539% +18 mo

Most-delayed active Phase 3 trials

Largest gap between the first-registered and current primary completion date.

TrialFirst plannedNowDelay
XePOHCAS
Invero Pharma, Inc. · Cardio-Met
2019-072029-04+117 mo
ALLELE
Pierre Fabre Medicament · Infectious
2020-112030-05-31+115 mo
CM-AT
Curemark · Neuro
2018-102028-01+111 mo
UX111
Ultragenyx Pharmaceutical Inc $RARE · Rare
2019-122029-03+111 mo
Masitinib (6.0)
AB Science · Neuro
2018-09-012027-12+111 mo
Elenestinib
Blueprint Medicines Corporation · Oncology
2023-082032-09-30+110 mo
PEDZ-K
AstraZeneca $AZN · Cardio-Met
2021-01-072030-02-21+109 mo
EPCORE™FL-2
Genmab $GMAB · Oncology
2028-10-052037-11+109 mo
PrTK03
Candel Therapeutics, Inc. · Oncology
2015-092024-08+107 mo
FORTIFY
AbbVie $ABBV · GI·Renal·Heme
2020-04-152029-02+106 mo
Cellgram-LC
Pharmicell Co., Ltd. · GI·Renal·Heme
2021-03-022029-12-01+105 mo
JR-141
JCR Pharmaceuticals Co., Ltd. · Rare
2021-06-302030-03-31+105 mo
Ublituximab
TG Therapeutics, Inc. · Neuro
2023-102032-05-31+104 mo
U-ENDURE
AbbVie $ABBV · GI·Renal·Heme
2019-01-302027-09+103 mo
Seladelpar 5 mg Capsule
Gilead Sciences $GILD · GI·Renal·Heme
2020-122028-11+95 mo

How this is calculated

Source: ClinicalTrials.gov, including each record's version history (the first registered version gives the original plan). Included: industry-sponsored trials that are recruiting, active or not yet recruiting, first registered at least 12 months ago. Excluded: records not updated for a long time (likely out of date), and changes of more than 10 years (almost always a re-used or abandoned record). "Late" means the primary completion date moved back more than 6 months; "on time" means within one month of the original.

Dates are self-reported by sponsors. A delay can reflect slower recruitment, a protocol change, a larger study or simply admin, so it says nothing on its own about whether a drug works. Information only, not investment or medical advice.